Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 2
2019 5
2020 2
2021 6
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases.
Servais L, Camino E, Clement A, McDonald CM, Lukawy J, Lowes LP, Eggenspieler D, Cerreta F, Strijbos P. Servais L, et al. Digit Biomark. 2021 Aug 5;5(2):183-190. doi: 10.1159/000517411. eCollection 2021 May-Aug. Digit Biomark. 2021. PMID: 34723071 Free PMC article. Review.
Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy.
Lilien C, Reyngoudt H, Seferian AM, Gidaro T, Annoussamy M, Chê V, Decostre V, Ledoux I, Le Louër J, Guemas E, Muntoni F, Hogrel JY, Carlier PG, Servais L; PreU7 Study Group. Lilien C, et al. Ann Clin Transl Neurol. 2021 Oct;8(10):1938-1950. doi: 10.1002/acn3.51417. Epub 2021 Aug 28. Ann Clin Transl Neurol. 2021. PMID: 34453498 Free PMC article. Clinical Trial.
E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019.
Pini J, Siciliano G, Lahaut P, Braun S, Segovia-Kueny S, Kole A, Hérnando I, Selb J, Schirinzi E, Duong T, Hogrel JY, Olmedo JJS, Vissing J, Servais L, Vincent-Genod D, Vuillerot C, Bannwarth S, Eggenspieler D, Vicart S, Diaz-Manera J; eNMD group; Lochmüller H, Sacconi S. Pini J, et al. J Neuromuscul Dis. 2021;8(4):743-754. doi: 10.3233/JND-210655. J Neuromuscul Dis. 2021. PMID: 33843694 Free PMC article.
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study.
Annoussamy M, Seferian AM, Daron A, Péréon Y, Cances C, Vuillerot C, De Waele L, Laugel V, Schara U, Gidaro T, Lilien C, Hogrel JY, Carlier P, Fournier E, Lowes L, Gorni K, Ly-Le Moal M, Hellbach N, Seabrook T, Czech C, Hermosilla R, Servais L; NatHis-SMA study group. Annoussamy M, et al. Ann Clin Transl Neurol. 2021 Feb;8(2):359-373. doi: 10.1002/acn3.51281. Epub 2020 Dec 24. Ann Clin Transl Neurol. 2021. PMID: 33369268 Free PMC article.
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
Mapperley C, van de Lagemaat LN, Lawson H, Tavosanis A, Paris J, Campos J, Wotherspoon D, Durko J, Sarapuu A, Choe J, Ivanova I, Krause DS, von Kriegsheim A, Much C, Morgan M, Gregory RI, Mead AJ, O'Carroll D, Kranc KR. Mapperley C, et al. J Exp Med. 2021 Mar 1;218(3):e20200829. doi: 10.1084/jem.20200829. J Exp Med. 2021. PMID: 33156926 Free PMC article.
Cytoskeletal Control of Antigen-Dependent T Cell Activation.
Colin-York H, Javanmardi Y, Skamrahl M, Kumari S, Chang VT, Khuon S, Taylor A, Chew TL, Betzig E, Moeendarbary E, Cerundolo V, Eggeling C, Fritzsche M. Colin-York H, et al. Cell Rep. 2019 Mar 19;26(12):3369-3379.e5. doi: 10.1016/j.celrep.2019.02.074. Cell Rep. 2019. PMID: 30893608 Free PMC article.
17 results